Results 51 to 60 of about 74,341 (223)
Avaliação de parâmetros laboratoriais e clínicos de pacientes portadores de leucemia mielóide crônica submetidos ao tratamento com mesilato de imatinibe e sua relação com alterações observadas no estroma da medula óssea Correlation between laboratory and clinical parameters of chronic myeloid leukemia patients treated with imatinib mesylate and its relationship with stromal changes observed in bone marrow biopsy [PDF]
, 2007 Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-graduação em FarmáciaA leucemia mieloide cronica (LMC) e uma doenca mieloproliferativa clonal, responsavel por 14% de todos os casos de ...
Caroline R. de Jesus +1 more
core +1 more source
Haematologica, 2019 Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg (‘high-dose’) imatinib accelerated achievement of a deep molecular ...
Christian Michel +60 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian +12 more
wiley +1 more source
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
Journal of Community Hospital Internal Medicine Perspectives, 2018 Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation ...
Adnan Asif Parvez Ghias +3 more
doaj +1 more source
Journal of Analytical Methods in Chemistry, 2021 In this study, The metabolites, metabolic pathways, and metabolic fragmentation mode of a tyrosine kinase inhibitor- (TKI-) imatinib in rats were investigated.
Sijiang Liu, Zhaojin Yu
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo +10 more
wiley +1 more source
Food Biomacromolecules, EarlyView.Non‐animal extracellular vesicles as bioactive‐compound carriers: compositional characteristics, engineering strategies, and biofunctions. Abstract Animal‐derived extracellular vesicles (EVs) were widely used for bioactive compound delivery but constrained by complex origins, potential immunogenicity, and pathogen contamination.
Jiahao Yu +6 more
wiley +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Riaz ul-Haq +19 more
core
Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. [PDF]
PLoS ONE, 2010 The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure.
Jiye A +15 more
doaj +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Background Rectal gastrointestinal stromal tumors (GISTs) are rare, and their optimal surgical management remains controversial. This study compared clinicopathologic features and oncologic outcomes between total mesorectal excision (TME) and local excision (LE) to guide surgical strategy.
Byeo Lee Lim +6 more
wiley +1 more source